Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Ligusticum wallichii is a traditional Chinese medicinal herb containing tetramethylpyrazine as its primary bioactive compound. It works by improving blood circulation through vasodilation and antiplatelet aggregation mechanisms.
Origin & History
Ligusticum wallichii (Chuanxiong) is a perennial herb from the Apiaceae family native to China, particularly growing in Sichuan and Yunnan provinces. The rhizome and root are harvested as the medicinal source, typically processed through aqueous decoction, ethanol extraction, or isolation of specific compounds like ligustrazine.
Research Narrative (Provisional)
Limited human clinical evidence exists, with one RCT (PMID: 1301850) treating 158 patients with transient ischemic attack showing superiority of Ligusticum wallichii over aspirin. Most evidence comes from preclinical studies, including rat myocardial infarction models (PMC4150451) and bronchial asthma research (PMID: 7841753), with no large-scale RCTs or meta-analyses identified.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Ligusticum wallichii (Chuanxiong) rhizome contains negligible macronutrients in therapeutic dosing (typically 3–9g dried herb or 1–2g extract). Primary bioactive compounds include: tetramethylpyrazine (ligustrazine) at approximately 0.1–0.5% dry weight — the principal vasoactive alkaloid; ferulic acid at 0.02–0.05% dry weight — a phenolic acid with antioxidant and antiplatelet activity; senkyunolide A and Z-ligustilide (phthalide lactones) comprising roughly 1–5% of volatile oil fraction; and cnidilide and butylidenephthalide as additional phthalides. Polysaccharide content ranges 5–8% dry weight contributing mild immunomodulatory activity. Calcium, potassium, and magnesium are present in trace mineral amounts typical of root herbs but are not clinically significant contributors. Bioavailability note: tetramethylpyrazine demonstrates rapid oral absorption (Tmax ~1 hour) but short half-life (~2–3 hours), necessitating divided dosing; ferulic acid bioavailability is enhanced in aqueous decoctions versus raw powder; Z-ligustilide is volatile and degrades with prolonged high-heat processing.
Reported Mechanism (Provisional)
Ligusticum wallichii's primary bioactive compound tetramethylpyrazine inhibits platelet aggregation by blocking calcium channels and reducing thromboxane A2 production. The herb promotes vasodilation through nitric oxide pathway activation and antagonizes vasoconstriction mediated by endothelin-1. Additional phthalide compounds enhance microcirculation by improving red blood cell deformability and reducing blood viscosity.
Clinical Narrative (Provisional)
One randomized controlled trial with 158 participants demonstrated Ligusticum wallichii's 89.2% effectiveness rate for treating transient ischemic attacks, significantly outperforming aspirin's 61.7% rate. Preclinical studies show cardiovascular benefits including improved left ventricular ejection fraction and reduced myocardial infarct size. However, human clinical evidence remains limited with most research conducted in animal models. The available evidence suggests moderate support for cerebrovascular applications but requires larger clinical trials for definitive therapeutic recommendations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.